FROM AIR FORCE TO HYPERSONIC FUTURE: ÉLCIO GERÔNIMO DE OLIVEIRA'S JOURNEY IN BRAZILIAN AEROSPACE DEVELOPMENT (ENGLISH VERSION)
Introdução: A entrevista com Élcio Gerônimo de Oliveira, conduzida pelo repórter Luis, apresenta a trajetória profissional de um pesquisador brasileiro com experiência na Força Aérea Brasileira e no meio acadêmico, com foco em sistemas espaciais e veículos hipersônicos. Objetivos: Documentar a carreira e contribuições de Élcio para o desenvolvimento aeroespacial brasileiro, destacando sua transição da carreira militar para a acadêmica e sua participação em projetos estratégicos, especialmente o projeto 14X. Métodos: A entrevista foi estruturada em blocos temáticos, abordando a carreira militar, a experiência acadêmica e, com maior detalhamento, o envolvimento no projeto do veículo hipersônico 14X. Foram realizadas perguntas abertas, permitindo ao entrevistado compartilhar sua experiência e conhecimento técnico. Resultados: Élcio descreveu sua progressão na Força Aérea Brasileira, desde pesquisador até vice-chefe da Diretoria de Espaço, destacando o desenvolvimento de veículos lançadores, sistemas de navegação inercial e o projeto SARA. Relatou sua transição para a carreira acadêmica, incluindo sua experiência como professor na Universidade de Luleå, na Suécia. Élcio detalhou sua coordenação no projeto 14X, um veículo hipersônico que alcançou Mach 7, com perspectivas de atingir Mach 10. Discussão: A entrevista revela a importância da cooperação internacional e da transferência de tecnologia, exemplificada pela doação do primeiro laboratório de hipersônica do Brasil. Evidencia também os desafios técnicos na construção de veículos hipersônicos e o potencial dessas tecnologias para aplicações militares e civis. Conclusão: A carreira de Élcio Gerônimo de Oliveira exemplifica a contribuição brasileira para pesquisa aeroespacial avançada, demonstrando a capacidade nacional de desenvolver tecnologias estratégicas como veículos hipersônicos, apesar das limitações de recursos, e apontando possibilidades futuras para o transporte e exploração espacial.
Read ArticleANTIBIOTIC SUSCEPTIBILITY OF ESCHERICHIA COLI ISOLATE FROM URINARY TRACT INFECTION OF THALASSEMIC PATIENTS IN THI-QAR PROVINCE
Escherichia coli (E. coli) is the most common type of pathogen that causes Urinary tract infection disease. It can be presented as a pathogenic or non-pathogenic strain and found not only in the animal but also in the human intestine. This bacterium can cause opportunistic infection when the human host comprised of thalassemia patients or changes the healthy hemostatic flora. This study aimed to analyze the presence of bacteria in thalassemia patients with urinary tract infection. A total of 303 samples were collected during the period from August 2019 to January 2020 from thalassemia patients who suffered from urinary tract infection. The results showed that there were 6.9% of patients infected with E. coli, 2.6% of patients were infected with S. aureus, 0.7% with both Proteus and Klebsiella, while 89.1% of patients had a negative sample for bacteria. Also, the incidence of urinary tract infections in females is higher than in males. Besides, its occurrence in rural areas is higher than in city residents. Moreover, among 16 antibiotics tested to sensitize bacteria to antibiotics, Imipenem showed 100% efficacy on all isolated bacteria. In contrast, Netilmicin showed 80.1% efficacy, Gentamycin 80.1%, and Amikacin 76.2%. Ampicillin, Aztreonam, Amoxicillin-Clavulanic Acid, Tetracycline, and Ticarcillin-Clavulanic Acid, did not show any effectiveness toward the bacteria while other antibiotics showed different activities. Furthermore, the isolated microbes from thalassemia patients were the highest resistance to antibiotics in comparison with other studies, and this antibiotic-resistant may be due to the weakening of the patient's immune status and frequent blood taking and the antibodies it contains.
Read ArticleRESEARCH LANDSCAPE OF REPURPOSED MEDICATIONS IN CANCER TREATMENT: A MULTI-DATABASE BIBLIOMETRIC ANALYSIS OF ELEVEN OFF-PATENT THERAPEUTICS
Background: Drug repurposing offers potential advantages for cancer therapy development, particularly when utilizing medications with established safety profiles and expired patents. While individual repurposed medications have been investigated for oncological applications, comprehensive comparative analyses of research distribution patterns across multiple therapeutic candidates appear limited in the literature. Understanding these patterns may provide insights into research priorities and potential knowledge gaps. Aim: This exploratory study was designed to quantify and compare the volume of scientific literature examining the anticancer potential of eleven selected off-patent medications across different pharmacological classes. Methods: Bibliometric searches were conducted across five databases (Google Scholar, BVS, PubMed, NIH, and Science.gov) using standardized search terms combining each medication name with "cancer" and "cancer treatment." The selected medications included ivermectin, fenbendazole, mebendazole, albendazole, metformin, propranolol, disulfiram, valproic acid, thalidomide, dexamethasone, and hydroxychloroquine. Basic statistical analyses were performed to examine the distribution patterns and correlations within the database. Results: The search yielded 3,226,066 total publications with considerable variation in distribution patterns. Dexamethasone accounted for the largest proportion (1,538,058 publications, 47.68%), followed by metformin (697,172 publications, 21.61%). Some medications with smaller overall publication volumes demonstrated higher proportions of treatment-specific research, such as fenbendazole (87.82%), disulfiram with copper (86.54%), and hydroxychloroquine with zinc (75.21%). The Herfindahl Index indicated a high concentration of research attention (0.2870). Discussion: The findings suggest substantial variation in research attention across the selected medications. While some medications dominate the literature, others with focused treatment-specific research may warrant further investigation. The inverse relationship observed between total publication volume and treatment specificity suggests that research patterns in this field may be more complex than absolute publication counts indicate. Conclusions: This preliminary bibliometric assessment reveals an uneven distribution of research attention among repurposed medications being investigated for cancer applications. These patterns may inform future research prioritization, though further qualitative analysis would be valuable to assess the clinical significance of these quantitative observations.
Read Article